-
A New Hope: FDA Approves Atrebioz (zilurgisertib) for FOP Treatment
NASDAQ: $MIRM A Breakthrough for Rare Disease Patients The landscape of treatment for Fibrodysplasia Ossificans Progressiva (FOP) has officially changed. The FDA has recently approved Atrebioz (zilurgisertib), providing a significant new therapeutic option for both adult and pediatric patients living with this incredibly rare and debilitating condition. Understanding FOP FOP is a progressive genetic disorder…
-
A Breakthrough in Rare Disease Care: FDA Approves Pasatru (garetosmab) for FOP
NASDAQ: $REGN A New Chapter for FOP Patients For individuals living with Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating genetic disorder, the medical landscape has just shifted significantly. The FDA has officially approved Pasatru (garetosmab), a new therapeutic option designed to help manage this challenging condition. Understanding FOP FOP is a rare genetic condition…